Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | NR1I2 | O75469 | 12/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2292224 | 0.94 | NR1I2 (0.56) | HPGDNR1I2ALDH1A1MEN1KMT2A | |
| SCHEMBL5285074 | 0.93 | LMNA (0.53) | HPGDNR1I2ALDH1A1MEN1KMT2A | |
| SCHEMBL5292819 | 0.93 | NR1I2 (0.48) | HPGDNR1I2ALDH1A1MEN1KMT2A | |
| SCHEMBL5300596 | 0.93 | HPGD (0.50) | HPGDNR1I2ALDH1A1MEN1KMT2A | |
| SCHEMBL5300317 | 0.93 | NR1I2 (0.48) | HPGDNR1I2ALDH1A1MEN1KMT2A | |
| SCHEMBL2299260 | 0.92 | HPGD (0.48) | HPGDNR1I2ALDH1A1MEN1KMT2A | |
| SCHEMBL5290026 | 0.92 | AKR1C3 (0.49) | HPGDNR1I2ALDH1A1MEN1KMT2A | |
| SCHEMBL2292244 | 0.91 | HPGD (0.62) | HPGDNR1I2ALDH1A1MEN1KMT2A | |
| SCHEMBL5410518 | 0.91 | NR1I2 (0.61) | HPGDNR1I2ALDH1A1MEN1KMT2A | |
| SCHEMBL5300268 | 0.91 | NR1I2 (0.61) | HPGDNR1I2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ALCATEL LUCENT (FR) | 2006-06-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ITGB5, ITGA5, ITGB1 | HPGD 2856/4885NR1I2 1911/4885ALDH1A1 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.